Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2015
At a glance
- Drugs ATHX 105 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Athersys
- 10 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment, as reported by ClinicalTrials.gov.
- 08 May 2008 This trial is expected to begin recruitment in the second half of 2008.
- 04 Mar 2008 New trial record.